Over the past two years, Merck (NYSE: MRK) has faced several challenges, resulting in a decline in the company's share price.

Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

New Jersey’s pharma sector faces new layoffs as Merck cuts 204 jobs and Bristol Myers Squibb plans 110 reductions amid ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Layoff filings show UnitedHealth’s Optum units planning the largest set of early-2026 job reductions among major healthcare ...

Valo Health Inc. is in line for upfront and potential milestone payments totaling up to over $3 billion under its new ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

Dividend growth picked up from companies in the first half of November, with 6 companies announcing 10%+ increases. Learn ...

Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary ...

ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and ...

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to ...